

SAVE THE DATE



3 Half days of interactive discussions

19th & 20th
October
2020

19th
November
2020


10:00am - 2:30pm EASTERN TIME
(New York / Washington DC)

Better understand the heart failure
guidelines process and its implications



Why attend a Guidelines Forum on heart failure?

8th edition
Digital Forum



Guidelines increasingly shape clinical practice. Their development and implementation is a critical issue for all stakeholders interested in better patients outcomes.

A better understanding of the processes involved in guidelines development will help companies that develop drugs, biomarkers, and devices to adapt and improve their research and development programmes for the future.

This could also translate into earlier and more efficient development of diagnostic and therapeutic tools for patients.

**FULLY DIGITAL FORUM ON
A SECURE INTERACTIVE
PLATFORM**

About TMA

The Translational Medicine Academy (TMA) is an international academic Foundation with focused activities in Mission Critical Areas of high public health importance having significant professional and patient therapeutic and educational gaps.

Format

A series of short presentations and discussions with a focus on practical examples, case studies and interactivity between Faculty members.

The format is strictly academic with discussions among experts. Participants can transmit written questions during the program and participate in ad hoc discussions at the end of each day.

Who should attend?

Attendees include industry representatives with interest in clinical trials, product development, market access, guidelines development and implementation, patients' advocacy specialists, clinical research organizations and payers.

Expert Panel

Speakers and discussants who will address these topics have been selected from among the top-level North American and international experts in cardiology who participate in the regular update of guidelines. The faculty also comprises clinicians with a strong interest in translational and patient-centered medicine. They will be able to transmit written questions to the faculty.

Practical discussions

How do guidelineers deal with the available evidence and what are their expectations in this respect? What criteria must a product or an intervention meet to be recommended by heart failure guidelines? What are the most frequent reasons for failure? Why may guidelines of geographically distinct origins but dealing with the same evidence occasionally reach different conclusions? What should be done to avoid that guidelines being lost in translation? How can we adapt the guidelines for low and middle income countries?

Why a Heart Failure Guidelines Forum?

Objective: to better understand the Heart Failure guidelines development process and its implications.

Participants: multidisciplinary panel of leading international experts with guideline-making experience.

Discussion topics: latest trial evidence, ongoing research and controversial issues that have implications for the development of clinical practice guidelines

Educational objectives

1. Better understand the guideline development process.
2. Review the latest scientific evidence regarding drugs, devices and biomarkers
3. Analyse the latest hot topics regarding guidelines and their implications in clinical practice.
4. Design studies and plan analyses for future trials

This event is registered with MedTech Europe and declared (provisionally) compliant: <https://www.ethicalmedtech.eu/>

Monday 19th October 2020

10:00am - 10:15am: Welcome / Introductions

10:15am - 11:15am: Session 1 – Heart failure guidelines process – Rules of engagement

- How are the US guidelines developed?
- How are the ESC guidelines developed?
- COVID-19 era : effects on clinical trials outcomes and reliability of evidence
- How to reconcile new FDA and CMS pathways with guideline writing
- A journal editor perspective
- The totality of evidence approach

11:15am - 11:45am: Session 2 – Endovascular approaches for functional mitral regurgitation (FMR) and tricuspid regurgitation (TR)

- Proportionate and disproportionate FMR
- The RESHAPE-HF2 view
- Is it better to significantly reduce versus eliminate FMR? Should clipping be the comparator in future trials to answer this question?
- Discussion: what can this mean for guidelines?

11:45am – 12:00pm: BREAK

12:00pm - 1:20pm: Session 3 – New approaches for better care of co-morbidities in HF - discussion options

- Cardio-renal protection: Treatment with SGLT2 inhibitors
- Iron deficiency
- Prevention of HF in Diabetes
- Treatment of Diabetes in HF
- Hyperkalemia

1:20pm - 2:20pm: Session 4 – New devices for the management of HF - discussion options

- Treating sleep apnea
- Barostim
- CCM
- Septal shunts
- Telemedicine
- Focus on MCS

2:20pm – 2:30pm: Ad hoc Q & A session (part 1)

Tuesday 20th October 2020

10:00am - 10:05am: Welcome

10:05am - 10:45am: Session 5 – Biomarkers for Acute HF

- Biomarker approaches to special problems (Procalcitonin in AHF to guide therapy and/or Diagnosing AMI in HF)
- Natriuretic peptides – all equal in new onset HF & chronic HF ?
- GFR assessment

10:45am - 11:15am: Session 6 – Treatment algorithm for Acute HF

- AHF position papers in the making

11:15am - 12:00pm: Session 7 – Treatment algorithm for HFmrEF and HFpEF

- Are we ready for a full algorithm?
- Or just selected recommendations?

12:00pm – 12:15pm: BREAK

12:15pm - 1:15pm: Session 8 – Treatment algorithms for HFrEF – Part 1

- With a focus on Mortality and Morbidity

1:15pm - 2:00pm: Session 9 – Treatment algorithms for HFrEF – Part 2

- With a focus on symptoms, QoL and functional capacity

Thursday 19th November 2020

10:00am - 10:15am: Welcome and summary of past discussions

10:15am - 11:15am: Session 10 – New HF trial results

- GALACTIC-HF
- AFFIRM-HF
- Other new trial data

11:15am - 12:00pm: Session 11 – Revisiting possible treatment algorithms after the AHA (part 1)

- Acute HF
- HFpEF & HFmrEF

12:00pm - 12:15pm: BREAK

12:15pm - 1:30pm: Session 12 – Revisiting possible treatment algorithms after the AHA (part 2)

- HFrEF – M&M oriented
- HFrEF – symptoms

1:30pm - 2:00pm: Session 13 – Guidelines implementation and International cascade guidelines

2:00pm - 2:25pm: Ad hoc Q & A session (part 3)

2:25pm - 2:30pm: Conclusions

Preliminary information

8th edition
Digital Forum

HEART FAILURE
GUIDELINES
FOR U M 

Chairs



Prof. William Abraham

MD, FACP, FACC, FAHA, FESC,
FRCPE

Professor of Medicine,
Physiology, and Cell Biology
College of Medicine,
Distinguished Professor, Division
of Cardiovascular Medicine, the
Ohio State University, USA



Prof. Stefan Anker

MD, PhD, FESC

Professor of cardiology and
Cachexia Research, Department
of Cardiology Charité Campus
Virchow-Klinikum Berlin,
Germany



Prof. Javed Butler

MD, MPH, MBA

Professor and Chairman of the
Department of Medicine at the
University of Mississippi in Jackson,
Mississippi, USA, Patrick H. Lehan
Chair in cardiovascular Research,
Professor of physiology



Prof. Andrew Coats

DM, DSc, MBA, AO

President-elect, Heart Failure
Association of the ESC, Academic
Vice-President Monash-Warwick
Alliance, Monash University,
Melbourne, Australia, University
of Warwick, Coventry, UK

Contact us

Organization

Charles Schoen - Operations Director

Tel.: +33 (0) 6 08 18 77 08

Email: charles.schoen@tmacademy.org

Registration

Yann Colardelle

Tel.: + 33 (0) 6 71 91 99 77

E-mail: yanncol@mededgs.com

Faculty (in progress)

Speakers

—● G. Bakris

●— J. Ezekowitz

—● G. Filippatos

●— G. Fonarow

—● A.Hernandez

●— J. Januzzi

—● J. Lindenfeld

●— A.Maisel

—● M. Packer

●— I. Piña

—● B. Pitt

●— P. Ponikowski

—● G. Rosano

●— N. Stockbridge

—● G. Stone

—● J. Teerlink

●— F. Zannad

—● S. Zieroth

●— B. Zuckerman

Observer

—● P. Heidenreich

www.tmacademy.org

An opportunity to meet **a panel of international experts** in **Heart Failure**